HUE054037T2 - CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra - Google Patents

CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra

Info

Publication number: HUE054037T2
Authority: HU; Hungary
Prior art keywords: methods; activable antibody; conjugates against; active conjugates; active
Prior art date: 2017-10-14

Application number

HUE18797311A

Other languages

English (en)

Inventor

Shweta Singh

Jennifer Hope Richardson

Laura Patterson Serwer

Jonathan Alexander Terrett

Susan E Morgan-Lappe

Tracy Henriques

Sherry L Ralston

Marvin Robert Leanna

Ilaria Badagnani

Sahana Bose

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-14

Filing date

2018-10-12

Publication date

2021-08-30

2018-10-12 Application filed by Abbvie Inc filed Critical Abbvie Inc

2021-08-30 Publication of HUE054037T2 publication Critical patent/HUE054037T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HUE18797311A 2017-10-14 2018-10-12 CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra HUE054037T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762572467P	2017-10-14	2017-10-14

Publications (1)

Publication Number	Publication Date
HUE054037T2 true HUE054037T2 (hu)	2021-08-30

Family

ID=64110112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE18797311A HUE054037T2 (hu)	2017-10-14	2018-10-12	CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra

Country Status (36)

Country	Link
US (3)	US20190111150A1 (hu)
EP (2)	EP3834846A1 (hu)
JP (2)	JP7374891B2 (hu)
KR (4)	KR102385495B1 (hu)
CN (1)	CN111278467B (hu)
AR (1)	AR115178A1 (hu)
AU (1)	AU2018346969A1 (hu)
BR (1)	BR112020007302B1 (hu)
CA (1)	CA3077730A1 (hu)
CL (1)	CL2020000977A1 (hu)
CO (1)	CO2020005685A2 (hu)
CR (1)	CR20200206A (hu)
CY (1)	CY1123968T1 (hu)
DK (1)	DK3691692T3 (hu)
DO (1)	DOP2023000150A (hu)
EC (1)	ECSP20025198A (hu)
ES (1)	ES2864013T3 (hu)
HR (1)	HRP20210436T8 (hu)
HU (1)	HUE054037T2 (hu)
IL (1)	IL273586A (hu)
LT (1)	LT3691692T (hu)
MA (1)	MA50752B1 (hu)
MD (1)	MD3691692T2 (hu)
MX (1)	MX2020003723A (hu)
PE (1)	PE20210125A1 (hu)
PH (1)	PH12020550417A1 (hu)
PL (1)	PL3691692T3 (hu)
PT (1)	PT3691692T (hu)
RS (1)	RS61596B1 (hu)
RU (2)	RU2771292C2 (hu)
SG (1)	SG11202003378WA (hu)
SI (1)	SI3691692T1 (hu)
SM (1)	SMT202100184T1 (hu)
TW (2)	TWI780237B (hu)
UY (1)	UY37931A (hu)
WO (1)	WO2019075417A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130116404A1 (en)	2011-11-08	2013-05-09	Case Western Reserve University	Targeted non-invasive imaging probes of egfr expressing cells
LT3292149T (lt) *	2015-05-04	2022-03-10	Cytomx Therapeutics, Inc.	Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
KR102760654B1 (ko)	2017-06-07	2025-02-04	리제너론 파마슈티칼스 인코포레이티드	효소 내재화를 위한 조성물 및 방법
MA51796A (fr)	2018-02-07	2020-12-16	Regeneron Pharma	Procédés et compositions pour l'administration de protéines thérapeutiques
WO2019183633A1 (en)	2018-03-23	2019-09-26	Case Western Reserve Univeristy	Psma targeted conjugate compounds and uses thereof
SG11202011232VA (en)	2018-05-17	2020-12-30	Regeneron Pharma	Anti-cd63 antibodies, conjugates, and uses thereof
IL297148A (en) *	2020-04-08	2022-12-01	Janssen Biotech Inc	Compositions and methods for blood-brain barrier delivery
US20210317188A1 (en) *	2020-04-09	2021-10-14	Cytomx Therapeutics, Inc.	Compositions containing activatable antibodies
EP4429654A1 (en)	2021-11-09	2024-09-18	Case Western Reserve University	Psma targeted conjugate compounds and uses thereof
WO2024026474A1 (en) *	2022-07-29	2024-02-01	Regeneron Pharmaceuticals, Inc.	Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2025024334A1 (en)	2023-07-21	2025-01-30	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0279862B1 (en)	1986-08-28	1993-11-03	Teijin Limited	Cytocidal antibody complex and process for its preparation
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
DE69303494T2 (de)	1992-11-13	1997-01-16	Idec Pharma Corp	Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US7666817B2 (en)	2005-08-31	2010-02-23	The Regents Of The University Of California	Cellular libraries of peptide sequences (CLiPS) and methods of using the same
JP6035009B2 (ja)	2007-08-22	2016-11-30	ザリージェンツオブザユニバーシティオブカリフォルニア	活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
NZ585556A (en) *	2007-11-07	2012-07-27	Celldex Therapeutics Inc	Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
JP5851842B2 (ja)	2009-01-12	2016-02-03	サイトムエックスセラピューティクス, インク.CytomX Therapeutics, Inc.	改変した抗体組成物、それを作製および使用する方法
JP5925116B2 (ja) *	2009-04-29	2016-05-25	ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド	Ｅｒｇモノクローナル抗体
US9309325B2 (en)	2009-05-07	2016-04-12	The Regents Of The University Of California	Antibodies and methods of use thereof
MX350200B (es) *	2011-02-01	2017-08-30	Genmab As	Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
ES2694165T3 (es) *	2012-01-31	2018-12-18	Sbi Biotech Co., Ltd.	Anticuerpo anti-fosfolipasa D4
US9309510B2 (en)	2012-08-10	2016-04-12	Cytomx Therapeutics, Inc.	Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) *	2013-02-05	2014-05-21	浙江大学	一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
KR102237803B1 (ko) *	2013-12-25	2021-04-09	다이이찌 산쿄 가부시키가이샤	항 trop2 항체-약물 컨쥬게이트
LT3292149T (lt) *	2015-05-04	2022-03-10	Cytomx Therapeutics, Inc.	Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
CN106237341B (zh) *	2016-07-12	2019-07-30	浙江大学	一种抗体偶联药物及其制备方法和应用

2018
- 2018-10-12 PH PH1/2020/550417A patent/PH12020550417A1/en unknown
- 2018-10-12 KR KR1020207013706A patent/KR102385495B1/ko active Active
- 2018-10-12 DK DK18797311.0T patent/DK3691692T3/da active
- 2018-10-12 MA MA50752A patent/MA50752B1/fr unknown
- 2018-10-12 MD MDE20200822T patent/MD3691692T2/ro unknown
- 2018-10-12 PL PL18797311T patent/PL3691692T3/pl unknown
- 2018-10-12 ES ES18797311T patent/ES2864013T3/es active Active
- 2018-10-12 US US16/159,559 patent/US20190111150A1/en not_active Abandoned
- 2018-10-12 CA CA3077730A patent/CA3077730A1/en active Pending
- 2018-10-12 CR CR20200206A patent/CR20200206A/es unknown
- 2018-10-12 TW TW107136020A patent/TWI780237B/zh active
- 2018-10-12 CN CN201880069577.4A patent/CN111278467B/zh active Active
- 2018-10-12 KR KR1020237014403A patent/KR20230070046A/ko active Pending
- 2018-10-12 TW TW111137633A patent/TW202330039A/zh unknown
- 2018-10-12 RU RU2020115713A patent/RU2771292C2/ru active
- 2018-10-12 SG SG11202003378WA patent/SG11202003378WA/en unknown
- 2018-10-12 HR HRP20210436TT patent/HRP20210436T8/hr unknown
- 2018-10-12 MX MX2020003723A patent/MX2020003723A/es unknown
- 2018-10-12 SM SM20210184T patent/SMT202100184T1/it unknown
- 2018-10-12 KR KR1020227011264A patent/KR20220045088A/ko not_active Ceased
- 2018-10-12 JP JP2020520804A patent/JP7374891B2/ja active Active
- 2018-10-12 PT PT187973110T patent/PT3691692T/pt unknown
- 2018-10-12 UY UY0001037931A patent/UY37931A/es not_active Application Discontinuation
- 2018-10-12 EP EP20209320.9A patent/EP3834846A1/en active Pending
- 2018-10-12 EP EP18797311.0A patent/EP3691692B8/en active Active
- 2018-10-12 RU RU2022111211A patent/RU2022111211A/ru unknown
- 2018-10-12 WO PCT/US2018/055733 patent/WO2019075417A1/en active Application Filing
- 2018-10-12 LT LTEP18797311.0T patent/LT3691692T/lt unknown
- 2018-10-12 BR BR112020007302-4A patent/BR112020007302B1/pt active IP Right Grant
- 2018-10-12 AU AU2018346969A patent/AU2018346969A1/en active Pending
- 2018-10-12 KR KR1020227044475A patent/KR102529359B1/ko active Active
- 2018-10-12 PE PE2020000380A patent/PE20210125A1/es unknown
- 2018-10-12 HU HUE18797311A patent/HUE054037T2/hu unknown
- 2018-10-12 AR ARP180102966A patent/AR115178A1/es not_active Application Discontinuation
- 2018-10-12 SI SI201830233T patent/SI3691692T1/sl unknown
- 2018-10-12 RS RS20210341A patent/RS61596B1/sr unknown
2020
- 2020-03-25 IL IL273586A patent/IL273586A/en unknown
- 2020-04-09 CL CL2020000977A patent/CL2020000977A1/es unknown
- 2020-05-07 CO CONC2020/0005685A patent/CO2020005685A2/es unknown
- 2020-05-13 EC ECSENADI202025198A patent/ECSP20025198A/es unknown
- 2020-11-25 US US17/105,402 patent/US20210145978A1/en not_active Abandoned
2021
- 2021-03-22 CY CY20211100239T patent/CY1123968T1/el unknown
2023
- 2023-05-19 US US18/320,869 patent/US20240115724A1/en not_active Abandoned
- 2023-07-27 DO DO2023000150A patent/DOP2023000150A/es unknown
- 2023-10-25 JP JP2023183034A patent/JP2024012366A/ja active Pending

Also Published As

Publication number	Publication date
KR20230004932A (ko)	2023-01-06
TWI780237B (zh)	2022-10-11
DK3691692T3 (da)	2021-03-22
AR115178A1 (es)	2020-12-09
EP3691692B1 (en)	2020-12-30
TW201927815A (zh)	2019-07-16
RU2771292C2 (ru)	2022-04-29
HRP20210436T8 (hr)	2022-01-07
US20210145978A1 (en)	2021-05-20
HRP20210436T1 (hr)	2021-04-30
CA3077730A1 (en)	2019-04-18
SI3691692T1 (sl)	2021-04-30
RU2020115713A3 (hu)	2022-02-25
CN111278467A (zh)	2020-06-12
CR20200206A (es)	2021-02-18
BR112020007302A2 (pt)	2020-09-29
PE20210125A1 (es)	2021-01-19
JP7374891B2 (ja)	2023-11-07
PT3691692T (pt)	2021-03-29
EP3691692B8 (en)	2021-05-26
ES2864013T3 (es)	2021-10-13
CO2020005685A2 (es)	2020-05-15
PL3691692T3 (pl)	2021-07-19
EP3691692A1 (en)	2020-08-12
SG11202003378WA (en)	2020-05-28
AU2018346969A1 (en)	2020-04-23
TW202330039A (zh)	2023-08-01
ECSP20025198A (es)	2020-06-30
US20240115724A1 (en)	2024-04-11
KR20220045088A (ko)	2022-04-12
KR102529359B1 (ko)	2023-05-09
BR112020007302B1 (pt)	2023-01-31
MX2020003723A (es)	2020-07-22
RS61596B1 (sr)	2021-04-29
DOP2023000150A (es)	2023-08-31
KR102385495B1 (ko)	2022-04-15
US20190111150A1 (en)	2019-04-18
EP3834846A1 (en)	2021-06-16
RU2020115713A (ru)	2021-11-16
LT3691692T (lt)	2021-05-10
PH12020550417A1 (en)	2021-04-12
IL273586A (en)	2020-05-31
SMT202100184T1 (it)	2021-05-07
MA50752A (fr)	2020-08-12
MD3691692T2 (ro)	2021-05-31
JP2020537649A (ja)	2020-12-24
JP2024012366A (ja)	2024-01-30
UY37931A (es)	2019-04-30
MA50752B1 (fr)	2021-03-31
KR20200070324A (ko)	2020-06-17
WO2019075417A1 (en)	2019-04-18
CN111278467B (zh)	2024-07-30
KR20230070046A (ko)	2023-05-19
RU2022111211A (ru)	2022-05-05
CY1123968T1 (el)	2022-05-27
CL2020000977A1 (es)	2020-09-11

Publication	Publication Date	Title
HUE054037T2 (hu)	2021-08-30	CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra
IL272089A (en)	2020-03-31	Compounds, compositions and methods
IL265449A (en)	2019-05-30	Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
IL264654B1 (en)	2023-05-01	Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
SG11202003782XA (en)	2020-05-28	Triple-chain antibody, method for preparation and use thereof
ZA201806576B (en)	2020-01-29	Antibodies, pharmaceutical compositions and methods
HUE054103T2 (hu)	2021-08-30	Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
HUE053737T2 (hu)	2021-07-28	Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
HUE053332T2 (hu)	2021-06-28	Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
IL264161A (en)	2019-02-28	Tgfb antibodies, methods, and uses
LT3283521T (lt)	2023-12-27	Vaistų konjugatai, apimantys antikūnus prieš klaudiną 18.2
IL247659A0 (en)	2016-11-30	Antibodies against immunogenic glycopeptides, a preparation containing them and their use
HUE049081T2 (hu)	2020-09-28	GP120 elleni neutralizáló antitestek és alkalmazásuk
HUE053619T2 (hu)	2021-07-28	Anti-CD123 antitestek és konjugátumok és ezek származékai
IL278877A (en)	2021-01-31	Amino-pyrazinecarboxamide compounds, conjugates and their uses
HUE059338T2 (hu)	2022-11-28	Ellenanyagok, alkalmazások és eljárások
IL270363B2 (en)	2025-03-01	N-(AZAARYL)CYCLOLACTAM–1–CARBOXAMIDE DERIVATIVE – METHOD FOR ITS PREPARATION AND USE
DK3640207T3 (da)	2022-04-11	Molekularsi scm-15, syntesefremgangsmåde dertil og anvendelse deraf
EP3200823A4 (en)	2018-07-18	Multivalent meditopes, meditope-binding antibodies and uses thereof
DK3612579T3 (da)	2022-02-14	Pultrudat, fremstilling og anvendelse heraf
DK3265123T5 (da)	2024-09-16	Antistoffer, anvendelser og fremgangsmåder
EP3386460A4 (en)	2019-10-09	ORAL DEVICE, ARRANGEMENT AND METHOD FOR USE THEREOF
GB201614162D0 (en)	2016-10-05	Antibodies, uses thereof and conjugates thereof
HK1254864A1 (zh)	2019-07-26	Hbed-二膦酸鹽/酯、其放射金屬軛合物和它們作為治療診斷劑的用途
HUE063621T2 (hu)	2024-01-28	ß-interferon elleni ellenanyagok és alkalmazásuk